Form 4: ESSA Pharma Director Scott Requadt Reports Acquisition of 50,000 Options
SEC Form 4 Filing
Director Scott Requadt reports acquiring 50,000 options of ESSA Pharma Inc.
Summary
- On March 28, 2024, Scott Requadt, a director of ESSA Pharma Inc., filed a Form 4 with the SEC.
- The form reports a transaction on March 25, 2024, where Requadt acquired 50,000 options with an exercise price of $9.04.
- These options are exercisable from March 25, 2025, and expire on March 25, 2034.
- Following the transaction, Requadt directly owns 50,000 derivative securities (options).
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting an insider transaction. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company directors.
Stakeholder Impact
- The acquisition of options by a director could be perceived positively by shareholders, indicating confidence in the company's future performance.
Key Dates
| Date | Description |
|---|---|
| 03/25/2024 | Date of transaction: Acquisition of 50,000 options. |
| 03/25/2025 | Options become exercisable. |
| 03/25/2034 | Options expiration date. |
| 03/28/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.